Entity

Time filter

Source Type

Kalamazoo, MI, United States

The present invention relates to cancer therapies and methods of using the same. In particular, the present invention provides methods of monitoring and improving the administration of cancer therapies, wherein the cancer is mediated by the BCL2 oncogene, via markers of disease identification, disease progression, drug resistance, and/or treatment efficacy.


Patent
ProNAi Therapeutics and Novosom AG | Date: 2014-12-12

The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.


Patent
Novosom AG and ProNAi Therapeutics | Date: 2013-01-28

The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.


Patent
ProNAi Therapeutics | Date: 2014-03-14

The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition genes implicated in many diseases.


News Article | January 13, 2014
Site: www.finsmes.com

ProNAi Therapeutics, Inc., a Plymouth, MI-based developer of nucleic acid therapeutics, closed a $12m Series C financing round. The round was led by Capital Midwest Fund and includes existing and new investors. Founded in 2004 and led by Mina Sooch, CEO, ProNAi Therapeutics is working to discover and develop new drugs to treat cancer and other genetically defined diseases with its proprietary DNA interference (DNAi®) technology. Its lead compound, PNT2258, is in Phase II trials against BCL2-driven lymphomas with a pipeline of DNAi leads for over 30 cancer and non-cancer targets, including CMYC and KRAS. The company intends to use the funds to expand cancer studies for PNT2258 in defined Lymphoma patients.

Discover hidden collaborations